London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
In the IPO they talked of aiming at 10-12 holdings only with max 15% in single stock. Initial value approx £7.85m gross (£7.5m net???). So might have meant £700 to £800k in most stocks with absolute max £1.2m
In Placings IIG seem to get say around £250k. Of course initial values often then trade at a premium like MSYS
LST £1M convertible bond pre-IPO
BioQ $1m convertible notes pre-IPO
MSYS £250k @ 0.1p
EVG £175k @ 8p
KMK £250k @ 15p
Wonder if they will topup placings with purchases in market?
If not I guess total number of positions are likely to be 15 to 20.
Not that I see it as a problem! Very smart team. Glad to be holding as lti.
In some cases I am using drops post placings to buy into same stocks
https://twitter.com/ShareTalkNews/status/1357717620313780227?s=20
https://www.share-talk.com/rob-naylor-incoming-ceo-intuitive-investments-group-iig-l-interview/
Rob Naylor, incoming CEO Intuitive Investments Group (#IIG.L) Interview. The newly established investing company, seeking to provide investors with exposure to a portfolio concentrating on fast-growing and/or high potential Life Sciences businesses
Been following IIG with interest .
Made a purchase this morning, though it did show as a sell, strange that.
What’s the view on the latest news ?
And what’s the general opinion here ?
Muckled
Thank you Patxi. That makes sense now.
Yes it was an online broker (XO) and i need to fill in a form.
This looks like a good opportunity, the management team seem to have a lot of experience. I am hoping this should give me some exposure to pre listing companies with a lot of growth potential.
Its already up 5p since I started looking at them!
Today's news seems pretty good to me. £250k invested at 0.1p in MSYS is already worth £800k at the current 0.325p MSYS share price.....
I'm unfamiliar with MSYS but might take a look now. Good to see David Evans is once again investing alongside IIG.
Something brewing possibly...
Thoughts?
Bullets from IPO admission.
https://quoteddata.com/2020/11/ipo-intuitive-investments/
Intuitive Investments Group plc (AIM:IIG), a closed-end investment company focussed on the life sciences sector, is pleased to announce its investment of US$1 million by way of unsecured convertible loan notes ("CLNs") in BioQ Pharma Incorporated ("BioQ").
BioQ is a well-established, commercial-stage, medical device and pharmaceutical company, addressing the infusible drugs market. BioQ's proprietary Invenious(TM) platform comprises a "connect-and-go" drug-device system combination, which can be utilised to improve the delivery of infusible medicines. BioQ's platform includes a bespoke unit-dose delivery solution for infusible drugs, whereby a diluent delivery system and administration line are combined in one self-contained, ready-to-use presentation. The key benefits of the platform include reduced cost and complexity compared to current infusion techniques. Further information on BioQ can be found at the company's website: https://bioqpharma.com/
Prime candidate for Nasdaq listing. Note the expiration date on CLN. Probably midway this year.
“ IIG's investment in BioQ consists of US$1 million of CLNs maturing on 1 November 2021. The terms of the CLN include a coupon of 10% that is accrued and paid on conversion or repayment, warrant coverage, and provisions for conversion into new equity at the time of a qualifying future fundraise (at a 35 per cent. discount to the price of such fundraise) or at maturity.”
LST is IIG's first investment from its pipeline of opportunities, following its successful IPO and Admission to AIM in December 2020.
LST is currently preparing to apply for the admission of its entire ordinary share capital to trading on the AIM market of the London Stock Exchange plc ("Admission"), which is expected during the first half of 2021. LST was incorporated on 13 January 2020 and has not undertaken any material trading. UK Circuits & Electronics Solutions Limited ("UKC"), a company controlled by the shareholders of LST, is intended to be the primary component of the LST group on Admission. In the year ended 30 November 2019, UKC posted group revenues of GBP5.6 million, a gross profit of GBP1.3 million and a net profit of GBP0.1 million. As at 30 November 2019, the net assets of UKC were GBP0.4 million. Additional information on LST can be found on its website: https://www.lightsciencetech.com/
“ initial applications in the controlled agriculture environment sector and a longer-term development application in non-invasive medical diagnostics.”
https://www.uktech.news/news/investment-news/vertical-farming-startup-light-science-technologies-funding-20210113
IIG will be considered 'complex' as it invests in higher risk, unlisted companies in a sector that is often 'hero or zero'.
A financial advisor (if used) would be required to talk you through the risk of financial loss before purchasing on your behalf. If acting alone, which I assume you are, your broker is highlighting that this stock is not for everyone, certainly not one to put your entire life savings in to. This should be considered a higher risk element of a balanced portfolio. There is a real risk that your investment may be worth less than you put in if you are a forced seller.
Did your broker direct you to an online test?
I use AJ Bell and they have a series of online questions such as "how much are you prepared to loose" (hint don't select £0), "what is your investment timeframe" (don't put 3-6 months), "are you knowledgeable about the stock market", "do you understand what a complex instrument is" and "how long have you been investing for".
A bit of common sense and you will be fine, if you do fail the test with honest answers then perhaps this one is not for you after all.
Yep. Thats why I bought a healthy chunk on placing - it reaches advantageous places that i cant personally reach myself.
Hi, I tried to buy some shares today but I was told this was a complex instrument requiring an appropriateness test. Can someone tell me why this is a complex instrument?
The irony of having to ask this question is not lost on me :-)
Hmmm. I have a decent stake already, but was hoping that the price would drift again so that I could get some more. Instead the price is going the other way. Thwarted again :o))
Here's today's news re a £1m CLN in BioQ:
https://www.investegate.co.uk/intuitive-invests-gp--iig-/rns/investment-in-bioq-pharma/202101210700023778M/
I note that the BioQ loan note has a maturity date of 1st November this year. Hopefully this indicates a possible IPO prior to that date - and if so it would presumably be in BioQ's home territory of the USA, which would likely bring about a very healthy premium.
Afternoon, been looking into the company - Their website is lacking on info, had a few emails from T&P, got a slight idea of what they are wanting to achieve - I am not invested yet, but been involved in DE businesses before.
Can anyone add more on IIG, add a bit more meat to the bone? The medicinal plants, is this is reference to medical cannabis. I have spent a number of years in this industry, I am trying to understand IIG's USP.
Nice find rivaldo, i was happy with the first investment RNS. This will be an interesting year ahead at least
https://martinflitton1.wixsite.com/privatepunter/post/following-the-winners
Great example of what IIG can achieve - with a pre-IPO investment at a discount.
me too...got in on the placing...good BOD lots of experience and lots of skin in the game, Evans invested a million in the launch. I reckon it won be long before they are doing deals so it's a case of watch and wait. Hopefully not for too long
RDOT . Same for me...will be interesting to see what they bring over the next few years.
The management have great professional background for the investments they are looking at. Im in early and will be a LTH :)